Cellbricks’ Post

Altura and its research partner Neighborhood Healthcare (FQHC) will present at the Festival of Biologics 2024 in San Diego on April 15 about the results of a grant-funded study related to building clinical trial and health research access and diversity via Community Health Centers. The study explored barriers preventing diverse populations from joining clinical studies and offers ways CHCs, life science companies and research organizations can help increase participation. If you would like a copy of the white paper, please email info@alturastudies.com. Thanks! #healthequity #clinicaltrials #healthaccess #chcs #lifescienceindustry

We've heard your concerns, and we're here to deliver!   In light of recent clinical setbacks and funding challenges, advancing your macrophage therapeutic pipeline may seem daunting. That's why we're excited to invite you to the 𝟲𝘁𝗵 𝗠𝗮𝗰𝗿𝗼𝗽𝗵𝗮𝗴𝗲-𝗗𝗶𝗿𝗲𝗰𝘁𝗲𝗱 𝗧𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 𝗦𝘂𝗺𝗺𝗶𝘁, your chance to learn from past mistakes, anticipate future challenges, and seize lucrative opportunities.   𝗦𝗲𝗲𝗸𝗶𝗻𝗴 𝗙𝘂𝗻𝗱𝗶𝗻𝗴?💸 Don't miss our crucial session on "𝘌𝘹𝘢𝘮𝘪𝘯𝘪𝘯𝘨 𝘵𝘩𝘦 𝘐𝘯𝘷𝘦𝘴𝘵𝘰𝘳 𝘗𝘦𝘳𝘴𝘱𝘦𝘤𝘵𝘪𝘷𝘦 𝘵𝘰 𝘚𝘦𝘤𝘶𝘳𝘦 𝘗𝘢𝘳𝘵𝘯𝘦𝘳𝘴𝘩𝘪𝘱𝘴 & 𝘈𝘥𝘷𝘢𝘯𝘤𝘦 𝘛𝘩𝘦𝘳𝘢𝘱𝘦𝘶𝘵𝘪𝘤 𝘗𝘰𝘵𝘦𝘯𝘵𝘪𝘢𝘭."   📖𝗥𝗲𝗮𝗱 𝗺𝗼𝗿𝗲 𝗶𝗻 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗮𝗴𝗲𝗻𝗱𝗮 - https://ter.li/m6xt76   This summit is an incredible opportunity to accelerate your research, refine strategies, and attract crucial investment in this promising space.   🌟In a field where many hesitate, this is your moment to lead. Gain exclusive insights and unmatched networking opportunities to position your company at the forefront of macrophage-directed therapies.   🎟️𝗚𝗿𝗮𝗯 𝗼𝗻𝗲 𝗼𝗳 𝗼𝘂𝗿 𝗱𝗶𝘀𝗰𝗼𝘂𝗻𝘁𝗲𝗱 𝗽𝗮𝘀𝘀𝗲𝘀 𝘄𝗶𝘁𝗵 𝘀𝗮𝘃𝗶𝗻𝗴𝘀 𝗼𝗳 𝘂𝗽 𝘁𝗼 $𝟵𝟬𝟬! - https://ter.li/9ir2pz   Join us and transform your challenges into success at the #MacrophageDirectedTherapiesSummit! 

Real-World Evidence plays a crucial role in shaping evidence-based decisions and enhancing the overall effectiveness of healthcare interventions. But what’s the best way to maximize the impact of real-world data? Find the answer in our next #ClimedoConnect webinar on January 25! Here’s a sneak peak of what we’ll discuss with Dr. Helene Vioix (Director Global Value Development Oncology at Merck): ✅ Engaging KTLs throughout the feasibility phase for invaluable insights ✅ Creating novel evidence and gaining Health Technology Assessment (#HTA) acceptance through innovative methodologies ✅ Leveraging KTL support to disseminate results to wider Key Opinion Leader (#KOL) groups ✅ Exploring an innovative approach that enhances traditional registries, navigating regulatory challenges Don't miss the opportunity to network with other industry professionals and ask Helene any questions you may have. Register here for free: https://lnkd.in/dhgi37SN #RWE #ClinicalTrials #HealthcareInnovation #MedicalResearch

In case you missed our webinar yesterday, Decoding the Impact of the IRA on Patients, you can watch the recording at https://buff.ly/4dYh7Lq. Don't miss part 2 of this webinar series, the IRA Impact on Innovation in Drug Development on November 12. Join us as we bring together perspectives from patient advocacy groups and biotech professionals to discuss the emerging concerns and explore actionable strategies to mitigate potential access limitations for patients. Panelists: - Candace DeMatteis, Policy Director, Partnership to Fight Chronic Disease - Catherine Sabatos-Peyton, CEO, Larkspur Biosciences Moderator: Martin Strebl-Bantillo, PhD, Principal, Strategy Consulting, Lumanity Register at https://buff.ly/4dWxhFq #InflationReductionAct #IRA #DrugDevelopment #PatientAdvocacy #Biotech #PatientAccess #HealthCarePolicy

Andrew attended World Orphan Drug Congress USA last week and shares his key take aways. "The conference, as ever, was a great way to connect with friends and peers in the rare disease community. Key themes in the access track were naturally, changes that are coming in Europe and the US, although the conference was not dominated by these. During the final day plenary sessions 2 of our current client companies took to the stage to discuss planning for access. Both talked about the need to plan early, resource your access and HEOR, and consider all options. Sage advice, especially given the complexity we see in are and ultra rare. Both talked about the need for choosing the right partners, which you can imagine gives a sense of pride, knowing that we are their partners. In other tracks we heard from patient advocates talking about the need for patients to be heard and incorporated into access decision making, along with great success stories where this is happening right now. It was also good to hear that investors are back at the table for biotech developers given the hiccups in ’22 and ’23 for longer term investment decisions. Patients living with rare conditions will ultimately benefit from these decisions." #raredisease #WODC #networking #marketaccess #heor

FREE conference today and tomorrow!!! If you are Sponsor in San Diego and have some free time today, come check out OCT Southern California at the Hyatt Regency La Jolla. There is an interesting session at 2PST: PANEL: Considerations for a Patient Centric Trial Design to Increase Trial Success - Exploring patient collaboration and the benefits it can bring to the sponsor and the patient. - Importance of good communication to the patients and how this can streamline trial timelines - Exploring how patients could, and should, be influencing decisions and the R&D process before study start-up. - How to optimize collaboration with patient advocacy organizations Patient perspective ‘Pain Points’ throughout various trials Speakers: Jessica Hatheway Jessica Hatheway MBA, Vice President, Clinical Operations, Daré Bioscience Constance Crowley Constance Crowley Executive Director/Senior Clinical Scientist, Arcturus Therapeutics Dr. Paul Grint Paul Grint Executive Chairman, Codagenix Nick Tresnowski Nick Tresnowski Director of Operations, LEAPCURE

In case you missed our webinar yesterday, Decoding the Impact of the IRA on Patients, you can watch the recording at https://buff.ly/3Ab0iPF. Don't miss part 2 of this webinar series, the IRA Impact on Innovation in Drug Development on November 12. Join us as we bring together perspectives from patient advocacy groups and biotech professionals to discuss the emerging concerns and explore actionable strategies to mitigate potential access limitations for patients. Panelists: - Candace DeMatteis, Policy Director, Partnership to Fight Chronic Disease - Catherine Sabatos-Peyton, CEO, Larkspur Biosciences Moderator: Martin Strebl-Bantillo, PhD, Principal, Strategy Consulting, Lumanity Register at https://buff.ly/4fewNvj #InflationReductionAct #IRA #DrugDevelopment #PatientAdvocacy #Biotech #PatientAccess #HealthCarePolicy

i-Cubed Advisory Board Member and Founder and CEO of BioTechquity Clinical Michelle McMurry-Heath, MD, PhD, was a panelist at the recent Innovations in Healthcare 2024 Annual Forum. The Annual Form attracts collaborators from across the globe, representing various industries, to exchange insights, ideas, and innovations for expanding access to affordable, quality healthcare. One of this year’s themes for innovation concerned clinical trials. “70% of drug development costs can be attributed to clinical trials. This is unsustainable and we are going to have to innovate if we are to be successful in bringing equitable access to therapeutics, especially in low and middle-income countries,” Dr. McMurry-Heath said.   One of our goals at i-Cubed is to identify the root causes of the barriers to running effective and efficient clinical trials and work with partners like Dr. McMurry-Heath and the Duke Global Health Innovation Center to implement solutions.   Visit the i-Cubed website to learn more about Dr. McMurry-Heath and our other Advisory Board members working to transform the world of clinical research: duke.is/AB

Looking forward to connecting with experts from >40 countries and discuss opportunities and challenges in our industry. See you in #Basel at #SwissBiotechDay!

Sponsors are turning to technology to improve efficiency and streamline workflows. While technology is having a positive impact on trials (accelerating the collection of higher quality data, for example), its introduction into clinical trial settings has resulted in unforeseen burdens on sites. In a recent article for ACRP - Association of Clinical Research Professionals, our Chief Product Officer Elisa Cascade shares findings from Advarra's 2023 Study Activation Survey Report, which revealed that a typical oncology study now uses about 22 (yes, 22!) different systems. Sites are already dealing with substantial administrative burdens, and with nearly two-thirds of respondents in Advarra’s survey reporting that the burden caused by technology is far greater than it was just five years ago, dealing with training, onboarding, and management on 22 different systems just isn't feasible. Elisa shares her insights around what we can do to navigate this challenge here: https://lnkd.in/gn7xbsBY #ClinicalResearch #ClinicalTrials #HealthcareTechnology #HealthcareInnovation